J Gynecol Oncol.
2021 Nov;32(6):e95. 10.3802/jgo.2021.32.e95.
Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 2020
- Obermair A
1 - Beale P2,3,4
- Scott CL5,6
- Beshay V7
- Kichenadasse G8,9
- Simcock B10
- Nicklin J11,12
- Lee YC13,14,15
- Cohen P16,17
- Meniawy T18,19
- Affiliations
-
- 1Queensland Centre for Gynaecological Cancer Research, The University of Queensland, Brisbane, QLD, Australia
- 2Department of Medical Oncology Concord Hospital, Concord, NSW, Australia
- 3Department of Medical Oncology Chris O’Brien Lifehouse, Camperdown, NSW, Australia
- 4Faculty of Medicine University of Sydney, Camperdown, NSW, Australia
- 5Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia
- 6Australia and Royal Women’s Hospital, Parkville, VIC, Australia
- 7Molecular Diagnostic Laboratory, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
- 8Flinders Centre for Innovation in Cancer, Flinders Medical centre/Flinders University, Bedford Park, SA, Australia
- 9South Australian Cancer Clinical network, Commission for excellence and innovation in health, Citicentre building Adelaide, SA, Australia
- 10Canterbury District Health Board. University of Otago, Dunedin, New Zealand
- 11Gynaecological Oncology, Royal Brisbane and Women's Hospital, Herston, QLD, Australia
- 12Faculty of Medicine, The University of Queensland, St Lucia, QLD, Australia
- 13Prince of Wales and Royal Hospital for Women, Randwick, NSW, Australia
- 14NHMRC Clinical Trials Centre, University of Sydney, NSW, Australia
- 15Faculty of Medicine, University of New South Wales, NSW, Australia
- 16Department of Gynaecological Oncology, St John of God Subiaco Hospital, Subiaco, WA, Australia
- 17Division of Obstetrics and Gynaecology, Faculty of Health and Medical Sciences, University of Western Australia, Crawley, WA, Australia
- 18Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia
- 19School of Medicine, University of Western Australia, Nedlands, WA, Australia
- KMID: 2526284
- DOI: http://doi.org/10.3802/jgo.2021.32.e95
Abstract
- Epithelial ovarian cancer (EOC) is among the top ten causes of cancer deaths worldwide, and is one of the most lethal gynecological malignancies in high income countries, with incidence and death rates expected to rise particularly in Asian countries where ovarian cancer is among the 5 most common cancers. Despite the plethora of randomised clinical trials investigating various systemic treatment options in EOC over the last few decades, both progression-free and overall survival have remained at approximately 16 and 40 months respectively. To date the greatest impact on treatment has been made by the use of poly (ADP-ribose) polymerase (PARP) inhibitors in women with advanced EOC and a BRCA1/2 mutation. Inhibition of PARP, the key enzyme in base excision repair, is based on synthetic lethality whereby alternative DNA repair pathways in tumor cells that are deficient in homologous recombination is blocked, rendering them unviable and leading to cell death. The Australia New Zealand Gynaecological Oncology Group (ANZGOG) is the national gynecological cancer clinical trials organization for Australia and New Zealand. ANZGOG's purpose is to improve outcomes and quality of life for women with gynecological cancer through cooperative clinical trials and undertaking multidisciplinary research into the causes, prevention and treatments of gynecological cancer. This review summarizes current ovarian cancer research and treatment approaches presented by Australian and New Zealand experts in the field at the 2020 ANZGOG webinar series entitled “Ovarian Cancer systems of Care”.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Hereditary Ovarian Cancer: Report of 6 Families
- Ovarian metastasis from pulmonary adenocarcinoma
- Advanced ovarian cancer: what should be the standard of care?
- A Case of Multiple Primary Cancer with Cervical Adenocarcinoma and both Ovarian Endometrioid Adenocarcinoma
- Epidermal Cyst-like Skin Metastasis in Ovarian Cancer Patient
